Summary: A groundbreaking study suggests that the future of Alzheimer’s treatment lies in “combination therapy” inspired by cancer treatment. Researchers found that pairing existing anti-amyloid antibodies with small molecules derived from resveratrol (found in grapes and berries) and curcumin (found in turmeric) creates a more effective “search and destroy” mission against toxic brain proteins.
Most importantly, this combined approach could allow doctors to use lower doses of powerful medications, significantly reducing the risk of life-threatening side effects like brain bleeding and swelling.
Key Facts
- The Combination Strategy: While current antibody treatments can be effective, they are risky. By adding micronutrient-derived molecules, researchers were able to neutralize amyloid protein clumping more efficiently than using either treatment alone.
- Safety First: High doses of standard Alzheimer’s antibodies can cause fatal brain swelling. This new approach acts as a “multiplier,” potentially allowing for smaller, safer drug doses without losing potency.
- Nature-Inspired Chemistry: Resveratrol (grapes, peanuts) and curcumin (turmeric) are natural anti-inflammatories. Waterloo scientists used their unique ability to block amyloid buildup as the foundation for this new drug cocktail.
- The “Chemo” Approach: Lead researcher Dr. Praveen Nekkar Rao noted that because Alzheimer’s is complex, it likely requires a multi-drug strategy—similar to how doctors treat cancer with various chemotherapy agents at once.
- A Warning on Supplements: The researchers explicitly state that eating these foods or taking over-the-counter supplements will not treat Alzheimer’s; the natural versions cannot reach the brain in high enough concentrations. The study is about designing synthetic versions of these molecules to pair with clinical drugs.
Source: University of Waterloo
A new study finds that combining the current medications for Alzheimer’s disease with small molecules derived from micronutrients found in grapes, berries, peanuts and turmeric is a safer and more effective way to treat the disease.
Individuals with Alzheimer’s have a buildup of toxic amyloid proteins in the brain. Researchers from the School of Pharmacy at the University of Waterloo combined amyloid-destroying small molecules with anti-amyloid antibodies that are already used in Alzheimer’s treatment.
They found that it neutralized the clumping of proteins that accumulate in the brain, leading to better outcomes.
Alzheimer’s is the major cause of dementia. Dementia affects nearly 750,000 people in Canada, with a million cases expected by 2030. Alzheimer’s has no cure and current medications only relieve a patient’s symptoms. Anti-amyloid antibody therapies on their own can slow the disease, but they also come with risks that can be fatal, including brain swelling and bleeding.
“We already know the small molecules resveratrol or curcumin, which are found in some common foods, block the buildup of amyloid,” said Dr. Praveen Nekkar Rao, a professor in the School of Pharmacy at Waterloo.
“What’s new and exciting is our combination of these molecules with the anti-amyloid antibodies. This approach could allow clinicians to use lower doses of antibodies, potentially reducing the risk of serious treatment-related side effects.”
Since there are few effective treatments for Alzheimer’s, researchers at Waterloo studied whether using two treatments together could work better than using just one. They chose resveratrol and curcumin because they are natural compounds known to reduce amyloid buildup and inflammation.
“I was inspired by chemotherapy, which involves taking multiple medications for effective treatment,” Nekkar Rao said. “Alzheimer’s is a complex disease, but there are very few combination therapy approaches. Our results show that the way forward is definitely combination therapy.”
The researchers emphasize that the study does not suggest that people should start consuming resveratrol or curcumin to prevent or treat dementia. You would have to consume an unsafe amount in order to reach the brain.
The next phase of the research will focus on designing next-generation drugs that can reach the brain more effectively, interact favourably with amyloids and pair seamlessly with antibody treatments.
Key Questions Answered:
A: Bioavailability is the issue. To get enough curcumin into your brain to actually break down amyloid plaques, you would have to consume an amount that is toxic to the rest of your body. Scientists are “engineering” these molecules to make them more effective at crossing the blood-brain barrier.
A: Yes, several anti-amyloid antibodies are FDA-approved (like Leqembi). However, their use is strictly monitored because they can cause ARIA (Amyloid-Related Imaging Abnormalities), which includes brain bleeding. This new study offers a way to keep the benefits of these drugs while lowering the danger.
A: The research is currently moving into the “next-generation drug design” phase. This means they are refining the molecules before moving into human clinical trials. It is a major step toward a safer, more comprehensive treatment for the 1 million Canadians expected to have dementia by 2030.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this Alzheimer’s disease research news
Author: Pamela Smyth
Source: University of Waterloo
Contact: Pamela Smytha – University of Waterloo
Image: The image is credited to Neuroscience News
Original Research: Closed access.
“Combination of Resveratrol and Curcumin with Anti-Amyloid Monoclonal Antibodies Aducanumab and Lecanemab Leads to Greater Inhibition of Amyloid-Beta Aggregation” by William Le Boeuf, Ahmed A. Hefny, Rahul C. Karuturi, and Praveen P. N. Rao. ACS Chemical Neuroscience
DOI:10.1021/acschemneuro.5c00760
Abstract
Combination of Resveratrol and Curcumin with Anti-Amyloid Monoclonal Antibodies Aducanumab and Lecanemab Leads to Greater Inhibition of Amyloid-Beta Aggregation
This study evaluated the antiamyloidogenic effects of the monoclonal antibodies aducanumab and lecanemab in combination with the small molecules resveratrol and curcumin.
The Aβ42 aggregation kinetics study revealed that both antibodies alone demonstrated 50–71% inhibition of Aβ42 fibrillogenesis, whereas their combination with resveratrol or curcumin resulted in markedly enhanced suppression of Aβ42 fibrillogenesis (89–97% inhibition), indicating a strong additive effect.
Electron microscopy studies confirmed a substantial reduction in fibril load following combination treatment with monoclonal antibodies and small molecules. In the cellular assays, antibody–small molecule combinations were nontoxic to mouse hippocampal HT22 neurons and significantly mitigated Aβ42-induced cytotoxicity, outperforming antibody monotherapy treatment.
Computational modeling suggested complementary binding modes, with antibodies targeting the N-terminal surface of Aβ42 assemblies and resveratrol or curcumin binding to internal regions.
Together, these findings provide proof-of-concept data to develop novel antiamyloid monoclonal antibody and small molecule combination strategies for treating Alzheimer’s disease.
